Furthermore, the authors reported the utility of PRAME/Melan A dual-label immunostaining and stressed the usefulness of PRAME IHC in the assessment of diagnostically challenging nodal melanocytic deposits, such as intraparenchymal nodal nevi, metastases confined to the capsular fibrous tissue, or in the setting of small metastases coexisting with a nodal nevus in the same lymph node. This evidence concerns the gene MLANA and nevus.